3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
Oxaliplatin
8
Fluorouracil
8
pembrolizumab
7
Paclitaxel
6
Trastuzumab
5
Leucovorin
5
Capecitabine
5
Specimen Handling
4
Radiation
4
Cisplatin
4
Carboplatin
4
tislelizumab
3
patritumab deruxtecan
3
Taxes
3
Radiotherapy
3
Nivolumab
3
ulixertinib
2
trastuzumab deruxtecan
2
trastuzumab biosimilar HLX02
2
durvalumab
2
Surgical Procedures, Operative
2
Ramucirumab
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Immunotherapy
2
Exercise
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.